However, even with these limitations, we believe valuable insights can be gained from broad based literature assessments of the genetic contribution in human common complex disease and in mouse phenotypic biology. More importantly, this suggests greater opportunities for systematic mining and analysis of published data and in cross comparison of archival molecular databases in both human and animal models of disease with regard to genetic variation, population comparisons, and integration with many different types of orthologous information. Pneumonitis as A Consequence of (Peg)Interferon-Ribavirin Combination Therapy for Hepatitis C: a Review of the Literature Combination of peginterferon and ribavirin is the current therapy for chronic hepatitis C infection (HCV). Interstitial pneumonitis is a rare side-effect of HCV therapy and is an important cause of dose reduction or discontinuation, impairing success of antiviral therapy. We performed a review of the literature in order to present diagnostic modalities and possible treatments for pneumonitis and to offer guidelines. We searched for cases where pneumonitis as a side-effect of HCV treatment was documented. First we performed a literature search via PubMed and Web of Science interface and second we searched three drug toxicity databases. We systematically analyzed all case reports with respect to clinical manifestations, type of treatment, and outcome. A literature search revealed 19 articles, containing 25 case descriptions, while we traced 33 cases from the drug toxicity databases. Pneumonitis presented with any of the combination of fever, dyspnea, and cough and can arise with any type of (conventional or pegylated) interferon. Mortality secondary to pneumonitis was seen in 7% of cases, exclusively with peginterferon α-2b. In most cases therapy was discontinued and steroids were started. Interferon-induced pneumonitis during HCV treatment is a severe complication and should be recognized in order to prevent further pulmonary damage and/or death. Hepatitis C (HCV) persists in up to 85% of patients and may result in liver cirrhosis and hepatocellular carcinoma [1] . The combination of peginterferon and ribavirin is the mainstay of treatment. Eradication of the virus can be achieved in up to 90% of chronic HCV patients, depending on a number of host-and virus-related factors [1, 2] . Successful treatment results in resolution of hepatic necroinflammation and regression of fibrosis.